Weigh Pros and Cons of SGLT2 Inhibitors for Kidney Protection

June 2019

You'll see more interest in using SGLT2 inhibitors (Invokana, etc) for renal protection in patients with type 2 diabetes.

Earlier findings from CV studies suggest SGLT2 inhibitors may protect the kidneys...probably by lowering intraglomerular pressure.

Now there's evidence in chronic kidney disease...mostly in patients with an eGFR below 60 mL/min.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote